Jasper Therapeutics to Present Preclinical Briquilimab Data at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
Jasper Therapeutics (Nasdaq: JSPR) will present preclinical data for briquilimab, their novel antibody therapy targeting c-Kit (CD117), at the ACAAI Annual Scientific Meeting in Boston from October 24-28, 2024. The therapy aims to treat mast cell driven diseases including chronic spontaneous urticaria, chronic inducible urticaria, and asthma.
Three presentations will showcase promising preclinical results demonstrating briquilimab's effectiveness in mast cell depletion and its ability to bind c-Kit with high potency. The studies include both in-vitro data and non-human primate research, supporting the drug's pharmacodynamics. All presentations will take place on Friday, October 25, 2024, in Exhibit Hall A.
Jasper Therapeutics (Nasdaq: JSPR) presenterà i dati preclinici per briquilimab, la loro nuova terapia a base di anticorpi mirata al c-Kit (CD117), durante il Meeting Scientifico Annuale ACAAI a Boston dal 24 al 28 ottobre 2024. La terapia si propone di trattare le malattie mediate dai mastociti, inclusa l'orticaria spontanea cronica, l'orticaria indotta cronica e l'asma.
Tre presentazioni metteranno in mostra risultati preclinici promettenti che dimostrano l'efficacia di briquilimab nell'eliminazione dei mastociti e la sua capacità di legarsi al c-Kit con alta potenza. Gli studi includono dati in vitro e ricerche su primati non umani, a supporto della farmacodinamica del farmaco. Tutte le presentazioni si terranno venerdì 25 ottobre 2024, nella Hall Espositiva A.
Jasper Therapeutics (Nasdaq: JSPR) presentará datos preclínicos para briquilimab, su novedosa terapia de anticuerpos dirigida a c-Kit (CD117), en la Reunión Científica Anual de ACAAI en Boston del 24 al 28 de octubre de 2024. La terapia tiene como objetivo tratar enfermedades impulsadas por mastocitos, incluyendo la urticaria espontánea crónica, la urticaria inducible crónica y el asma.
Tres presentaciones exhibirán resultados preclínicos prometedores que demuestran la efectividad de briquilimab en la depleción de mastocitos y su capacidad para unirse a c-Kit con alta potencia. Los estudios incluyen datos in-vitro e investigación en primates no humanos, apoyando la farmacodinamia del fármaco. Todas las presentaciones tendrán lugar el viernes 25 de octubre de 2024, en el Salón de Exposiciones A.
재스퍼 테라퓨틱스 (Nasdaq: JSPR)는 2024년 10월 24일부터 28일까지 보스턴에서 열리는 ACAAI 연례 과학 회의에서 c-Kit (CD117)을 겨냥한 새로운 항체 요법 브리퀼리맙에 대한 전임상 데이터를 발표할 것입니다. 이 요법은 마스트 세포가 유발하는 질환, 즉 만성 자발성 두드러기, 만성 유발성 두드러기 및 천식을 치료하는 것을 목표로 합니다.
세 가지 발표에서는 마스트 세포 감소에 대한 브리퀼리맙의 효과와 c-Kit에 강력하게 결합하는 능력을 입증하는 유망한 전임상 결과를 보여줄 것입니다. 연구에는 약물의 약리역학을 지원하는 인비트로 데이터와 비인간 영장류 연구가 포함됩니다. 모든 발표는 2024년 10월 25일 금요일에 전시홀 A에서 진행됩니다.
Jasper Therapeutics (Nasdaq: JSPR) présentera des données précliniques sur briquilimab, leur nouvelle thérapie par anticorps visant c-Kit (CD117), lors de la Réunion Scientifique Annuelle de l'ACAAI à Boston du 24 au 28 octobre 2024. Cette thérapie vise à traiter des maladies liées aux mastocytes, y compris l'urticairie spontanée chronique, l'urticairie induite chronique et l'asthme.
Trois présentations mettront en avant des résultats précliniques prometteurs montrant l'efficacité de briquilimab dans la déplétion des mastocytes et sa capacité à se lier au c-Kit avec une grande puissance. Les études incluent des données in vitro et des recherches sur des primates non humains, soutenant la pharmacodynamique du médicament. Toutes les présentations auront lieu le vendredi 25 octobre 2024, dans le Hall d'Exposition A.
Jasper Therapeutics (Nasdaq: JSPR) wird auf dem Jahrestreffen der ACAAI in Boston vom 24. bis 28. Oktober 2024 präklinische Daten zu briquilimab, ihrer neuartigen Antikörpertherapie, die auf c-Kit (CD117) abzielt, präsentieren. Die Therapie zielt darauf ab, durch Mastzellen bedingte Krankheiten zu behandeln, einschließlich chronischer spontaner Urtikaria, chronischer induzierbarer Urtikaria und Asthma.
Drei Präsentationen werden vielversprechende präklinische Ergebnisse zeigen, die die Wirksamkeit von briquilimab bei der Depletion von Mastzellen und seine Fähigkeit, sich hochpotent an c-Kit zu binden, demonstrieren. Die Studien umfassen sowohl in-vitro Daten als auch Forschung an nichtmenschlichen Primaten, die die Pharmakodynamik des Medikaments unterstützen. Alle Präsentationen finden am Freitag, den 25. Oktober 2024, in der Ausstellungshalle A statt.
- None.
- None.
REDWOOD CITY, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, is presenting data from preclinical studies evaluating briquilimab at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting, taking place October 24-28, 2024, in Boston, Massachusetts.
“We are pleased to present promising preclinical results from multiple studies at ACAAI this year,” said Wendy Pang, M.D., Ph.D., Senior Vice President, Research and Translational Medicine. “Both the in-vitro data and the non-human primate data generated in these studies provide further support for the pharmacodynamics of briquilimab, particularly its ability to bind c-Kit and drive mast cell depletion with relatively high potency.”
Details of the presentations are as follows:
Abstract Title: Briquilimab is Well-Tolerated and Effectively Depletes Tissue Resident Mast Cells in Non-Human Primates
Abstract ID: 8271
ePoster ID: R056
Presentation Date / Time: Friday, October 25, 2024; 3:45 p.m. - 4:00 p.m. EDT
Location: Exhibit Hall A
Abstract Title: Briquilimab Potently Inhibits Stem Cell Factor (SCF)/c-Kit Signaling, and Mast Cell (MC) Degranulation and Survival
Abstract ID: 8282
ePoster ID: R058
Presentation Date / Time: Friday, October 25, 2024; 4:15 p.m. - 4:30 p.m. EDT
Location: Exhibit Hall A
Abstract Title: Briquilimab Potently Blocks Stem Cell Factor (SCF)/c-Kit Signaling in Primary Human Mast Cells
Abstract ID: 8298
ePoster ID: R059
Presentation Date / Time: Friday, October 25, 2024; 4:30 p.m. - 4:45 p.m. EDT
Location: Exhibit Hall A
Copies of the presentations will be available on the ACAAI website as well as the Events & News – Events page on the Jasper Therapeutics IR website.
About Briquilimab
Briquilimab is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the cell-surface receptor c-Kit, also known as CD117, thereby inhibiting signaling through the receptor. This inhibition disrupts the critical survival signal, leading to the depletion of the mast cells via apoptosis which removes the underlying source of the inflammatory response in mast cell driven diseases such as chronic urticaria. Jasper is currently conducting clinical studies of briquilimab as a treatment in patients with CSU or with CIndU and is initiating a clinical study in patients with asthma. Briquilimab is also currently in clinical studies as a treatment for patients with LR-MDS and as a conditioning agent for cell therapies for rare diseases. To date, briquilimab has a demonstrated efficacy and safety profile in more than 160 dosed participants and healthy volunteers, with clinical outcomes in CIndU, and as a conditioning agent in severe combined immunodeficiency (SCID), acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), Fanconi anemia (FA), and sickle cell disease (SCD).
About Jasper
Jasper is a clinical-stage biotechnology company developing briquilimab, a monoclonal antibody targeting c-Kit (CD117) as a therapeutic for chronic mast and stem cell diseases such as chronic urticaria, asthma and lower to intermediate risk MDS and as a conditioning agent for stem cell transplants for rare diseases such as SCD, FA and SCID. To date, briquilimab has a demonstrated efficacy and safety profile in more than 160 dosed participants and healthy volunteers, with clinical outcomes in CIndU and as a conditioning agent in SCID, AML, MDS, FA, and SCD. For more information, please visit us at www.jaspertx.com.
Forward-Looking Statements
Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding briquilimab’s potential, including with respect to its potential in mast cell driven diseases such as CSU, CIndU, and asthma and its ability to bind c-Kit and drive mast cell depletion with relatively high potency; and Jasper’s presentation at ACAAI. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of Jasper and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Many actual events and circumstances are beyond the control of Jasper. These forward-looking statements are subject to a number of risks and uncertainties, including general economic, political and business conditions; the risk that the potential product candidates that Jasper develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; the risk that clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release; the risk that prior test, study and trial results may not be replicated in continuing or future studies and trials; the risk that Jasper will be unable to successfully market or gain market acceptance of its product candidates; the risk that prior study results may not be replicated; the risk that Jasper’s product candidates may not be beneficial to patients or successfully commercialized; patients’ willingness to try new therapies and the willingness of physicians to prescribe these therapies; the effects of competition on Jasper’s business; the risk that third parties on which Jasper depends for laboratory, clinical development, manufacturing and other critical services will fail to perform satisfactorily; the risk that Jasper’s business, operations, clinical development plans and timelines, and supply chain could be adversely affected by the effects of health epidemics; the risk that Jasper will be unable to obtain and maintain sufficient intellectual property protection for its investigational products or will infringe the intellectual property protection of others; and other risks and uncertainties indicated from time to time in Jasper’s filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2023 and subsequent Quarterly Reports on Form 10-Q. If any of these risks materialize or Jasper’s assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. While Jasper may elect to update these forward-looking statements at some point in the future, Jasper specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Jasper’s assessments of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.
Contacts:
Joyce Allaire (investors)
LifeSci Advisors
617-435-6602
jallaire@lifesciadvisors.com
Alex Gray (investors)
Jasper Therapeutics
650-549-1454
agray@jaspertx.com
Lauren Walker (media)
Real Chemistry
646-564-2156
lbarbiero@realchemistry.com
FAQ
What preclinical data will Jasper Therapeutics (JSPR) present at ACAAI 2024?
What diseases does Jasper Therapeutics' briquilimab target?
When and where will JSPR present their briquilimab research in October 2024?
What is the mechanism of action for Jasper Therapeutics' briquilimab?
